MX2020006689A - Composiciones de vcar y metodos de uso. - Google Patents
Composiciones de vcar y metodos de uso.Info
- Publication number
- MX2020006689A MX2020006689A MX2020006689A MX2020006689A MX2020006689A MX 2020006689 A MX2020006689 A MX 2020006689A MX 2020006689 A MX2020006689 A MX 2020006689A MX 2020006689 A MX2020006689 A MX 2020006689A MX 2020006689 A MX2020006689 A MX 2020006689A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- vcar
- vcars
- compositions
- disclosure
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se divulgan receptores de antígeno quimérico de VHH (VCAR), transposones de VCAR que codifican los VCAR de la divulgación, células modificadas para expresar los VCAR de la divulgación, y también métodos de preparación y métodos de uso de los mismos en terapia celular adoptiva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608571P | 2017-12-20 | 2017-12-20 | |
US201762608894P | 2017-12-21 | 2017-12-21 | |
PCT/US2018/066936 WO2019126574A1 (en) | 2017-12-20 | 2018-12-20 | Vcar compositions and methods for use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006689A true MX2020006689A (es) | 2020-11-06 |
Family
ID=65241306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006689A MX2020006689A (es) | 2017-12-20 | 2018-12-20 | Composiciones de vcar y metodos de uso. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210139557A1 (es) |
EP (1) | EP3728305A1 (es) |
JP (2) | JP2021507703A (es) |
KR (1) | KR20200116917A (es) |
CN (1) | CN112218885A (es) |
AU (2) | AU2018393110B2 (es) |
BR (1) | BR112020012555A2 (es) |
CA (1) | CA3086187A1 (es) |
IL (1) | IL275311A (es) |
MX (1) | MX2020006689A (es) |
RU (1) | RU2020123705A (es) |
SG (1) | SG11202005750TA (es) |
WO (1) | WO2019126574A1 (es) |
ZA (1) | ZA202003849B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109803978B (zh) * | 2016-09-07 | 2022-07-01 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
EA201992232A1 (ru) | 2017-03-22 | 2020-05-14 | Новартис Аг | Композиции и способы для иммуноонкологии |
MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
EP3802825A1 (en) * | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
CA3174777A1 (en) | 2020-04-14 | 2021-10-21 | Eric M. Ostertag | Compositions and methods for use in the treatment of cancer |
TWI828126B (zh) * | 2021-04-27 | 2024-01-01 | 中央研究院 | 用以治療高三酸甘油脂血症或其相關疾病的方法 |
EP4359541A2 (en) * | 2021-06-23 | 2024-05-01 | Editas Medicine, Inc. | Engineered cells for therapy |
CN113528437B (zh) * | 2021-07-07 | 2023-08-25 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种增强基因编辑效率的试剂盒及其应用 |
WO2023178297A1 (en) * | 2022-03-18 | 2023-09-21 | Obsidian Therapeutics, Inc. | Compact drug responsive domains for regulation of function/abundance and delivery of polypeptide payloads |
WO2024030214A2 (en) * | 2022-08-02 | 2024-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Brinp2-derived peptide compositions for treating obesity and weight management |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
ATE189124T1 (de) | 1991-07-02 | 2000-02-15 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
SK51695A3 (en) | 1992-10-19 | 1995-11-08 | Dura Pharma Inc | Dry powder medicament inhaler |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
EP0804561B1 (en) | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
PL327616A1 (en) | 1996-01-03 | 1998-12-21 | Glaxo Group Ltd | Inhaler |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
EA003665B1 (ru) | 1997-09-29 | 2003-08-28 | Нектар Терапьютикс | Перфорированные микрочастицы и способ их использования |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
EA201990959A1 (ru) * | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
ES2939760T3 (es) * | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
US10344285B2 (en) | 2014-04-09 | 2019-07-09 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
US9650428B2 (en) * | 2014-12-02 | 2017-05-16 | Roger Williams Hospital | Methods and compositions for treating cancer |
AU2016333898B2 (en) * | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
CN116082505A (zh) * | 2016-02-25 | 2023-05-09 | 细胞医学公司 | Pd-l1的结合成员 |
KR102633423B1 (ko) * | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
SG11201913175TA (en) * | 2017-06-30 | 2020-01-30 | The United States Of America As Represented By The Secretary | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
-
2018
- 2018-12-20 AU AU2018393110A patent/AU2018393110B2/en active Active
- 2018-12-20 MX MX2020006689A patent/MX2020006689A/es unknown
- 2018-12-20 KR KR1020207020443A patent/KR20200116917A/ko not_active Application Discontinuation
- 2018-12-20 BR BR112020012555-5A patent/BR112020012555A2/pt unknown
- 2018-12-20 RU RU2020123705A patent/RU2020123705A/ru unknown
- 2018-12-20 US US16/772,262 patent/US20210139557A1/en active Pending
- 2018-12-20 CN CN201880087741.4A patent/CN112218885A/zh active Pending
- 2018-12-20 WO PCT/US2018/066936 patent/WO2019126574A1/en unknown
- 2018-12-20 SG SG11202005750TA patent/SG11202005750TA/en unknown
- 2018-12-20 CA CA3086187A patent/CA3086187A1/en active Pending
- 2018-12-20 JP JP2020533629A patent/JP2021507703A/ja active Pending
- 2018-12-20 EP EP18842506.0A patent/EP3728305A1/en active Pending
-
2020
- 2020-06-11 IL IL275311A patent/IL275311A/en unknown
- 2020-06-24 ZA ZA2020/03849A patent/ZA202003849B/en unknown
-
2023
- 2023-07-27 AU AU2023208176A patent/AU2023208176A1/en active Pending
- 2023-08-18 JP JP2023133560A patent/JP2023154083A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL275311A (en) | 2020-07-30 |
AU2023208176A1 (en) | 2023-10-05 |
CN112218885A (zh) | 2021-01-12 |
CA3086187A1 (en) | 2019-06-27 |
AU2018393110A2 (en) | 2020-07-23 |
BR112020012555A2 (pt) | 2020-11-24 |
EP3728305A1 (en) | 2020-10-28 |
RU2020123705A (ru) | 2022-01-20 |
ZA202003849B (en) | 2021-07-28 |
JP2021507703A (ja) | 2021-02-25 |
KR20200116917A (ko) | 2020-10-13 |
SG11202005750TA (en) | 2020-07-29 |
JP2023154083A (ja) | 2023-10-18 |
AU2018393110A1 (en) | 2020-07-02 |
US20210139557A1 (en) | 2021-05-13 |
AU2018393110B2 (en) | 2023-04-27 |
WO2019126574A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
ZA202005556B (en) | Cartyrin compositions and methods for use | |
MX2022003995A (es) | Antigeno quimerico y receptores de celulas t y metodos de uso. | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
PH12019501227A1 (en) | Synthetic immune receptors and methods of use thereof | |
MX2020007266A (es) | Moleculas del receptor quimerico de engullido y metodos de uso. | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
MX2016012713A (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
MX2020003046A (es) | Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. | |
WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
PH12014502418B1 (en) | Enhanced affinity t cell receptors and methods for making the same | |
MX2017007575A (es) | Receptores de antígenos quiméricos de antígeno de maduración de células b. | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
MX2019003983A (es) | Caspasas inducibles y metodos de uso. | |
MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
MX2021011816A (es) | Metodos para produccion de celulas car-nk y uso de las mismas. | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. |